How Novartis AG stacks up

NVS · against 454 other Healthcare companies listed in US-listed

Growth

57/ 100

Below the middle of the pack.

Ranked #262 of 455 · scores higher than 42% of peers

Bars: peers in each 10-point band of the growth score

45 peers with a growth score of 50–59, including NVS · Click a bar to see the companies

Why growth scores 57?

Weighted metrics compared with all Healthcare companies.

Its metrics sit close to the Healthcare norm.

3-year revenue growth is close to the peer norm. 3-year revenue growth: 9.3% vs peer median 5.8%
Revenue growth is close to the peer norm. Revenue growth: 9.6% vs peer median 6.1%
faster growth in earnings per share: stronger than 63% of peers. Earnings per share growth: 21.2% vs peer median 9.8%

Metric by metric

Position: dot = NVS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	NVS	Peer median	Better than	Weight
Revenue growthHigher is better · 475 reported	9.6%	11.0%	47%	33%
Earnings per share growthHigher is better · 171 reported	21.2%	21.2%	50%	33%
3-year revenue growthHigher is better · 433 reported	9.3%	11.0%	45%	33%

Ranking by growth score

Top 5 and the companies ranked around NVS

Rank	Company	Market cap	Growth	Overall
1	Phathom Pharmaceuticals, Inc.PHAT · US-listed	460M USD	100	53
2	AnaptysBio, Inc.ANAB · US-listed	1.4B USD	99	73
2	CorMedix Inc.CRMD · US-listed	441M USD	99	81
2	ImmunityBio, Inc.IBRX · US-listed	9.5B USD	99	31
2	Insight Molecular Diagnostics Inc.IMDX · US-listed	87M USD	99	27
⋯
262	Bausch + Lomb CorporationBLCO · US-listed	7.4B USD	57	43
262	The Cooper Companies, Inc.COO · US-listed	12.2B USD

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score